© 2015 Elsevier Inc.The breakthrough of induced pluripotent stem cell technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC -derived cells is not well understood. Using a humanized mouse model reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs e…
Read more© 2015 Elsevier Inc.The breakthrough of induced pluripotent stem cell technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC -derived cells is not well understood. Using a humanized mouse model reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs exhibit local infiltration of antigen-specific T cells and associated tissue necrosis, indicating immune rejection of certain hiPSC-derived cells. In this context, autologous hiPSC-derived smooth muscle cells appear to be highly immunogenic, while autologous hiPSC-derived retinal pigment epithelial cells are immune tolerated even in non-ocular locations. This differential immunogenicity is due in part to abnormal expression of immunogenic antigens in hiPSC-derived SMCs, but not in hiPSC-derived RPEs. These findings support the feasibility of developing hiPSC-derived RPEs for treating macular degeneration.
